AHR and early-onset autosomal dominant Alzheimer disease: Dysregulation of the association between tryptamine levels, AHR signalling pathway activation, and MAO activity is observed in Alzheimer’s disease (AD), Parkinson’s disease (PD), autism spectrum disorder (ASD) and schizophrenia.